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Abstract:  
Glioblastoma have the poorest prognosis, and is characterized by excessive invasion and 
angiogenesis. To determine the invasive mechanisms, we previously used two glioma cell 
lines (J3T-1 and J3T-2) with different invasive phenotypes. The J3T-1 showed abundant 
angiogenesis and tumor cell invasion around neovasculature, while J3T-2 showed diffuse 
cell infiltration into surrounding healthy parenchyma. Microarray analyses were used to 
identify invasion-related genes in J3T-2 cells, and the expressed genes and their 
intracellular and intratumoral distribution patterns were evaluated in J3T-2 cell lines, 
human glioma cell lines, human glioblastoma stem cells, and human glioblastoma 
specimens. To determine the role of the invasion-related genes, invasive activities were 
evaluated in vitro and in vivo. Fibroblast growth factor 13 (FGF13) was overexpressed in 
J3T-2 cells compared to J3T-1 cells, and in human glioma cell lines, human glioblastoma 
stem cells, and human glioblastoma specimens, when compared to that of normal human 
astrocytes. Immunohistochemical staining and the RNA-seq (sequencing) data from the 
IVY Glioblastoma Atlas Project showed FGF13 expression in glioma cells in the invasive 
edges of tumor specimens. Also, the intracellular distribution was mainly in the cytoplasm 
of tumor cells and colocalized with tubulin. Overexpression of FGF13 stabilized tubulin 
4 
 
dynamics in vitro and knockdown of FGF13 decreased glioma invasion both in vitro and in 
vivo and prolonged overall survival of several xenograft models. FGF13 was negatively 
regulated by hypoxic condition. Silencing of FGF13 also decreased in vivo bevacizumab-
induced glioma invasion. In conclusion, FGF13 regulated glioma cell invasion and 
bevacizumab-induced glioma invasion, and could be a novel target for glioma treatment.  
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Introduction 
Glioblastoma has one of the poorest prognosis of intracranial tumors. Despite advances in 
basic and clinical studies, the outcomes of the patients remain poor, with the median survival 
time being 14.6 months (1). The causes of glioblastoma poor prognoses include its typical 
aggressive invasiveness, high angiogenesis, and proliferation. Recently, antiangiogenic 
treatments were used in clinical trials, however, no trials showed prolongation of overall 
survival (2) (3). Piao et al. reported that anti-vascular endothelial growth factor (anti-VEGF) 
therapy induced more invasive and treatment-resistant phenotypes (4). We have also shown 
that antiangiogenic therapy induced invasion in the orthotopic glioma models (5) (6).  
Glioma cells often migrate along brain structures including blood vessels and white matter 
tracts (7). We have previously established two novel invasive glioma cell line models, J3T-1 
and J3T-2 (8) (9) that mimicked the angiogenic and invasive phenotypes of human 
glioblastoma (10). The J3T-1 model formed vascular rich tumor masses, and in adjacent 
normal brain tissues, the tumor cells clustered around the neovasculature. In contrast, the 
J3T-2 model formed tumor masses with the invasion of single cells into the normal brain 
parenchyma along white matter tracts. Previously, we reported that annexin A2, which was 
abundantly expressed in the J3T-1 model, was involved in angiogenesis-dependent growth 
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of glioma (11).  
We further showed the presence of the newly identified invasion-related gene, fibroblast 
growth factor 13 (FGF13) [also named fibroblast growth factor homologous factor 2 (FHF2)], 
a member of the FGF family, in the invasive J3T-2 glioma model. Recent studies showed that 
FGF13 was widely distributed in the developing brain (12), was involved in neural 
differentiation in early development of Xenopus (13), and neural migration as a microtubule 
stabilizing protein (14). FGF13 had two alternative splicing forms: FGF13A that contained a 
nuclear localizing signal (NLS), and FGF13B that lacked the NLS. Nishimoto et al. reported 
that FGF13 was increased by SoxD and was involved in the activation of the MEK5-ERK5 
pathway in neuronal development (13). FGF13B regulated tubulin dynamics and was 
involved in neuronal motility (14).Currently, many studies have shown that microtubules 
appear in glioma and that tumor cell migration and invasion required dynamic reorganization 
of the cytoskeleton, including actin and microtubules (15, 16). As a result, microtubules have 
emerged as novel treatment targets to prevent tumor cell motility and invasion (17). 
In this study, we showed that FGF13 was highly overexpressed in glioma and the silencing 
of FGF13 expression reduced glioma cell invasion in vitro and in vivo, thereby regulating 
microtubule dynamics. Moreover, bevacizumab-induced glioma invasion was impaired by 
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knockdown of FGF13.  
 
Results 
FGF13 was highly expressed in the invasive glioma model, in various human glioma 
cell lines, and in human glioma stem cells. 
To investigate the difference of invasive ability, the difference of gene expression profiles 
between J3T-1 and J3T-2 cells were analyzed using microarray data (Supplementary Fig. 
1A). Gene Ontology (GO) enrichment analysis using these significantly regulated genes 
were performed (Table. 1 and 2). GO enrichment analysis of J3T-2 revealed that up-
regulated genes in J3T-2 were mostly related to microtubule (p = 0.011) and cytoskeletal 
protein expressing (p = 0.025). Among the genes in the microarray data involved in 
microtubule and cytoskeleton dynamics, FGF13 was overexpressed by 26.0-fold in J3T-2 
cells compared to that of the J3T-1 cells. Then, we performed quantitative reverse 
transcription-polymerase chain reaction (qRT-PCR) assays to confirm the reliability of the 
results from microarray analyses and determined that the relative expression levels of 
FGF13 in J3T-2 cells were significantly elevated by 14.8-fold (p < 0.01) compared with 
that of the J3T-1 cells (Supplementary Fig. 1B). 
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Next, we screened FGF13 mRNA levels in several human glioma cells by using qRT-PCR. 
The U87ΔEGFR, U251, and LNZ308 cells showed higher expression of FGF13 than that of 
the normal human astrocyte (NHA) cells, and were approximately 14.7 times, 2.6 times and 
4.1 times greater, respectively. Furthermore, the human glioblastoma-derived cancer stem 
cells (MGG8 and MGG23) that showed a diffusely invasive phenotype, like the J3T-2 (18) 
cells, also expressed higher FGF13 than that of the NHA cells (41.7 times and 1.91 times, 
respectively, p < 0.05). 
 
The expression of FGF13 protein was dominant in the cytoplasm in glioma cell lines 
and human glioma specimens, and FGF13 positive glioma cells were located in the 
invasive edge.  
Immunofluorescent staining of J3T-2 cells showed FGF13 (FGF13B) mainly localized in 
the cytoplasm (Fig. 1A). Next, we also performed immunohistochemical staining of human 
specimens. In normal brain tissues, FGF13 was mainly expressed in the nucleus of neurons 
(Fig. 1B). However, in glioblastoma patient specimens, FGF13 protein was dominant in the 
cytoplasm (Fig. 1C). The relative expression level of FGF13 mRNA and protein in human 
glioblastoma specimens were significantly correlated (p = 0.016, Fig. 1D). Western blotting 
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also showed FGF13B protein levels were higher than that of FGF13A in human 
glioblastoma specimens (Fig. 1E) and glioma cell lines (Fig. 2B). At the invasive edge, 
most tumor cells expressed FGF13 in the cytoplasm (Fig. 1C, right panel), however, in the 
tumor core, the number of FGF13 positive cells varied in each patient (Fig. 1C, left panel). 
The percentage of FGF13 positive tumor cells in the tumor core was 12.4%; however the 
percentage was markedly increased in the invasive edge of the glioblastoma (44.6%) (p < 
0.01, Fig. 1F). Data from the IVY Glioblastoma Atlas Project also showed that FGF13 was 
more expressed in the area of both the leading edge and infiltrating tumor than in the 
cellular tumor, perinecrotic zone, hyperplastic blood vessels, and microvascular 
proliferations (glioblastoma.alleninstitute.org) (Fig. 1G). Immunohistochemistry revealed 
that the microenvironment cells like endothelial cells and macrophages did not express 
FGF13 (Supplementary Fig. 2). We analyzed glioblastoma data from the Cancer Genome 
Atlas (TCGA) project and we found that FGF13 was more expressed in proneural and 
neural subtypes than in classical and mesenchymal types (Fig. 1H). For the FGF13 
expression based on glioma subtypes, data were analyzed using the Project Betastatis 
webpage (www.betastasis.com). Low grade glioma also exhibited FGF13 (Supplementary 
Fig. 3). 
10 
 
 
Silencing of FGF13 reduced the in vitro migration and invasion activity. 
To address the role of FGF13 in glioma, we examined the effect of FGF13 knockdown on 
cell migration and invasion. The siRNA silencing of FGF13 expression reduced FGF13 
mRNA expression in J3T-2 cells, and both FGF13 mRNA (Fig 2A) and protein levels (Fig. 
2B) in U87ΔEGFR, U251, and LNZ308 cells (p < 0.05; Fig. 2A and B). Transwell assays 
showed that silencing of FGF13 significantly reduced the migration of J3T-2 cells (p < 
0.05; Fig. 2C and D) and decreased the migration activity of U87ΔEGFR, U251 and 
LNZ308 cells (p < 0.05; Fig. 2C and D). Matrigel invasion assay also confirmed that 
silencing of FGF13 significantly reduced the invasion of J3T-2 and U87ΔEGFR (p < 0.05; 
Supplementary Fig. 2). In contrast, silencing FGF13 did not affect the migration and 
invasion of A172 and Gli36Δ5 cells (Supplementary Fig 4A, B and D) that expressed 
FGF13 at lower levels than that of the NHA cells (Supplementary Fig. 4C). 
Although the regulation of microtubules is usually involved in mitotic cell division in 
both normal and cancer cells, the WST-1 cell viability assay showed FGF13 did not alter 
glioma cell viability (p = 0.359, 0.742, 0.899, and 0.37 in J3T-2, U87ΔEGFR, U251, and 
LNZ308 cells, respectively; Fig. 2E). Furthermore, FGF13-silenced cells did not indicate 
11 
 
the increase of apoptosis (p = 0.82, 0.86, 0.70, and 0.62 in J3T-2, U87ΔEGFR, U251, and 
LNZ308 cells, respectively; Supplementary Fig. 5). We also evaluated whether knockdown 
of FGF13 alter cell morphology. However, silencing of FGF13 did not significantly change 
cell morphology (Supplementary Table 1 and 2). 
 
Silencing of FGF13 expression reduced the invasion and prolonged the survival time 
in xenograft glioma models bearing J3T-2 or human glioblastoma-derived cancer stem 
cells. 
To investigate the role of FGF13 in the xenograft glioma model, we generated J3T-2, 
MGG8 and MGG23 cells that had reduced FGF13 expression, using a lentivirus vector 
encoding a short hairpin RNA (shRNA) against canine or human FGF13. The lentivirus-
mediated shRNA reduced the relative FGF13 mRNA expression in J3T-2, MGG8, and 
MGG23 cells (p < 0.05; Fig. 3A, Fig. 4A and Supplementary Fig. 6A). The J3T-2, MGG8 
or MGG23 cells expressing FGF13 shRNA or non-targeting shRNA (scramble shRNA) 
were transplanted into the brain of the athymic mice or the severe combined 
immunodeficiency (SCID) mice, respectively.  
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To determine the invasive activity of J3T-2 cells, tissue slices were stained with anti-
vimentin antibody that reacted with canine but not mouse. Histological examination 
showed J3T-2 cells transfected with lentivirus encoding scramble shRNA (J3T-2 scramble 
shRNA; Fig. 3B and C) gradually migrated from the tumor center to the surrounding 
normal brain tissue and the edge of tumor. In contrast, the J3T-2 cells transfected with 
lentivirus encoding FGF13 shRNA (J3T-2 FGF13 shRNA) showed less invasive activity 
into normal brain than did the J3T-2 scramble shRNA cells and the edge of the tumor was 
clear of invasive cells (Fig. 3B and C). Knockdown of FGF13 did not affect the MIB-1 
labeling index (p = 0.81; Fig. 3D and E) and the number of apoptotic cells (p = 0.84, Fig. 
3F). The number of vessels in the tumor was also evaluated, however, there was no 
difference between the J3T-2 scramble shRNA and J3T-2 FGF13 shRNA samples (p = 0.51, 
Fig.3G, H). The percentage survival of the J3T-2 FGF13 shRNA treated samples was 
significantly greater than that of the J3T-2 scramble shRNA treated samples (median 
survival = 59.5 versus 49 days, respectively; p = 0.0015, Fig. 3I). 
We also investigated the role of FGF13 in glioma invasion using MGG8. 
Immunohistochemical examination of MGG8 showed these glioma cells spread from the 
injection site to the adjacent normal brain, like J3T-2 cells, and invaded along the corpus 
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callosum. Invasion activity was assessed from the number of tumor cells in the ipsilateral or 
contralateral cerebral cortex. There was a significant reduction of glioma cells invading into 
the cerebral cortex with MGG8 cells transfected with lentivirus encoding FGF13 shRNA 
(FGF13 shRNAs #1, #2; Fig. 4B and C) compared with MGG8 cells transfected with 
lentivirus encoding scrambled shRNA (scramble shRNA; Fig. 4B and C) (p < 0.01). 
However, knockdown of FGF13 did not affect the number of apoptotic MGG8 cells (p = 
0.71) (Fig. 4D), cell proliferation (p=0.85), and angiogenesis (p=0.46) in vivo. Kaplan-
Meier survival analysis resulted in the improvement of overall survival in the MGG8 
FGF13 shRNA #1, #2 injected animals (median survival = 61, 61.5 versus 55.5days, 
respectively; p < 0.02, Fig. 4E). Knockdown of FGF13 in MGG23 also significantly 
impaired glioma invasion and prolonged OS as well as MGG8 (Supplementary Fig. 6B, C, 
and F). 
 
FGF13B regulated microtubule dynamics and expression of FGF13 was negatively 
regulated by hypoxic conditions. 
To clarify the functional mechanism of FGF13 in glioma invasion, we focused on the 
interactions between FGF13 and tubulin dynamics in glioma. Immunohistochemical 
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staining showed that FGF13 was dominant in the cytoplasm of J3T-2 and colocalized with 
tubulin (Fig. 5A). Next, we isolated the fraction of soluble tubulin (tyrosinated tubulin; Tyr-
tubulin) and insoluble tubulin (acetylated tubulin; Ace-tubulin) from A172 cells transfected 
with the FGF13B plasmid or untransfected cell and treated with dimethyl sulfoxide 
(DMSO) or nocodazole, a microtubule destabilizer. The Tyr-tubulin or Ace-tubulin are 
markers for dynamic or stable microtubules, respectively. Western blotting showed Ace-
tubulin in normal A172 was decreased after treatment with nocodazole. However, FGF13B 
restored the level of Ace-tubulin in A172 cells treated with nocodazole (Fig. 5B). These 
results showed that FGF13B colocalized with tubulin and could stabilize the microtubule 
structures. We assessed the role of hypoxic conditions as a mechanism of affecting FGF13 
expression. FGF13-positive cells are dominant in the leading edge of tumors compared 
with the tumor core where hypoxic conditions exist. Western blotting of U87ΔEGFR and 
U251 confirmed that hypoxic condition negatively regulated FGF13 expression (Fig. 5C). 
Tumor cells cultured with 1% O2 or in medium containing deferoxamine mesylate showed 
the significant decrease of FGF13 expression (Fig. 5C and Supplementary Fig. 7).  
 
Silencing of FGF13 altered bevacizumab-induced glioma invasion. 
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Recently, bevacizumab has been used for glioblastoma treatment and shows benefits in 
progression-free-survival (PFS). However, bevacizumab was reported to induce invasion 
and this may lead to failures of prolongation of overall-survival (OS). We therefore 
investigated whether FGF13 also regulated bevacizumab-induced glioma invasion. 
First, we evaluated the expression of FGF13 after bevacizumab treatment in human 
glioma cell lines (Fig. 6A, Supplementary Fig. 8A and B), and human glioblastoma 
specimens (Fig. 6B and C), and found that the FGF13 expression was not altered after 
bevacizumab treatment. Western blotting of U87ΔEGFR and U251 showed almost the same 
expression level of FGF13 in all samples (Fig. 6A, Supplementary Fig. 8A, and B). We 
analyzed the FGF13 mRNA expression in five patients who had both pre- and post-
bevacizumab specimens using a previously published microarray data (19). No changes in 
FGF13 expression occurred after bevacizumab resistance (Fig. 6C, p=0.7278). 
Immunohistochemistry of FGF13 in our cohort also confirmed these data (Supplementary 
Fig. 8E).  
Next, we evaluated the role of FGF13 on bevacizumab-induced glioma invasion in vitro 
and in vivo using our previously reported bevacizumab-induced glioma invasion model (6). 
In vitro, double chamber assays showed that bevacizumab treatment significantly induced 
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glioma cell invasion, however, silencing of FGF13 decreased its invasion ability in both 
U87ΔEGFR and U251 cells (Supplementary Fig. 8C and D). We generated U87ΔEGFR 
cells expressing FGF13 shRNA or scramble shRNA (Fig. 6D) and transplanted each cell 
type in vivo into the brain of athymic mice. These mice were treated with either phosphate-
buffered saline (PBS) or bevacizumab. Mice in the PBS-treated group showed tumor 
masses with well-defined borders (Fig. 6E). However, in the bevacizumab-treated group, 
tumor cell invasion into surrounding normal tissues was induced and the tumor surface 
became irregular. We evaluated the depth of tumor invasion from the border of the tumor 
mass to the invaded cells. In U87ΔEGFR expressing scramble shRNA treated with 
bevacizumab, the mean depth of tumor invasion was 222.7 ± 34.9 µm. However, the depth 
of tumor invasion in the U87ΔEGFR expressing FGF13 shRNA samples treated with 
bevacizumab was remarkably decreased (mean, 111.9 ±16.8 µm, p < 0.05; Fig. 6E and F, 
Supplementary Fig. 8F and 8G). These results demonstrated that FGF13 was also involved 
in bevacizumab-induced glioma invasion.  
 
Discussion 
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In the present study, our findings suggested that FGF13 regulated microtubule dynamics 
and was involved in glioma invasion in vitro and in vivo. FGF13-related invasion was 
observed in both glioma non-stem cells and glioma stem cells. In addition, knockdown of 
FGF13 reduced bevacizumab-induced glioma invasion.  
 FGFs are widely distributed in both normal cells and cancer cells, and have a wide range 
of biological activities including cell proliferation, differentiation, and migration. In 
glioblastoma, several FGFs are known to be involved in pathogenesis or malignancy (20). 
Generally, FGFs act through their specific signals by binding to their receptors. However, 
FGF13 (FHF2) and other FHF family members (FGF11, FGF12 and FGF14) lack a 
secretory portion (SP) and therefore, FGF13 cannot be secreted or bind to cell surface FGF 
receptors. FGF13 is involved in the intracellular regulatory mechanism. Wu et al. reported 
that FGF13 regulated tubulin dynamics and invasive activity in neurons (14). Recently, the 
role of FGF13 in several cancers was also investigated. Okada et al. investigated the 
overexpression of FGF13 in HeLa cisR cells, which caused greater resistance to cisplatin. 
Cervical cancer patients with higher FGF13-positive cells showed poor prognosis after 
chemoradiotherapy (21). Yu et al. reported high expression of FGF13 in the cytoplasm, 
which was associated with a shortened time to biochemical recurrence after surgery in 
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prostate cancer (22). Less has been reported on the role of FGF13 in glioma. Saito et al. 
reported that FGF13 was highly expressed in γ-secretase inhibitor non-responder group 
when compared with responder group (23). Other studies reported the knockdown of SOX2 
changed FGF13 expression in glioblastoma (24) (25). However, the functional role of 
FGF13 in glioma was not fully elucidated. We found that cytoplasmic FGF13 regulated 
tubulin dynamics and glioma invasion.  
Recently, a number of studies found the cytoskeleton had an important role in glioma 
invasion (15) (26). The cytoskeleton consists of three major classes of structural components, 
including the microtubules (tubulin), actin filaments (actin), and intermediate filaments. In 
particular, microtubules and actin filaments are important in cell motility, and the crosstalk 
between these proteins is also important in cell migration (27). Both protein types are found 
in the cytoplasm but can be distributed in different parts of the cytoplasm. Some tubulin-
associated proteins have been reported to regulate glioma invasion. Dráberová et al. showed 
that silencing of the microtubules severing ATPase spastin in human glioblastoma cells 
inhibited cell motility (28). Song et al. demonstrated that silencing of the microtubule-
destabilizing phosphoprotein, stathmin, inhibited invasion and increased chemosensitivity of 
cancer stem cells (29). Also, many tubulin targeted therapies have been reported and showed 
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clinical benefit in glioma, including the microtubule stabilizing tubulin-binding agent 
patupilone (30), valproic acid (31), and tumor-treating fields (TTFields) (32). We first 
reported that FGF13 regulated glioma invasion by stabilizing microtubules in the leading 
edge of the tumor, and that silencing of FGF13 in vivo significantly prolonged the survival 
time of xenograft models. However, as previously reported, the survival benefit achieved by 
inhibiting invasion has little impact (26). Three possible reasons could explain the survival 
benefit derived from FGF13 deletion. First, it is possible that inhibition of glioma invasion 
may prolong xenograft survival. Whether inhibition of glioma invasion could prolong 
survival is not well-known. Nagai, et al. reported that regulation of invasion did not change 
the survival time (33). In contrast, Hayashi, et al. showed that inhibition of glioma invasion 
could significantly prolong survival time, but the number of survival benefit days was within 
15% of the OS time (26). Our xenograft models showed a survival benefit; however, the 
number of survival benefit days were 17.6%, 9.8%, and 14.7% in J3T-2, MGG8 and MGG23 
cells, respectively. These percentage are agreement with those of Hayashi et al. Second, it is 
also possible that other cellular processes related to microtubules were dysfunctional and this 
led to tumor cell death. Microtubules are highly dynamic structures that play important roles 
in cells, including vesicular transport processes other than during mitosis or migration. Third, 
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it is possible that FGF13 interacts with voltage-gated sodium channel proteins (Navs) in 
neurons (34) and may also interact with Navs in some cancers (21) (22). Navs is essential for 
glioma formation, so it may change the survival time in xenograft models. 
Randomized, placebo-controlled phase III trials of AVAglio and RTOG-0825 in newly 
diagnosed glioblastoma, with the addition of bevacizumab to radiotherapy plus 
temozolomide, could not prolong OS (2) (3). One reason for this result could be that anti-
VEGF therapy induced a phenotypic shift (35) toward a more invasive, aggressive, and 
treatment-resistant phenotype. Some signaling pathway such as MET (36), PI3K, or Wnt (37) 
are known to be activated to promote invasion after bevacizumab treatment. We showed that 
FGF13 was also involved in bevacizumab-induced glioma invasion in animal model. We 
thought FGF13 expression might be increased to induce invasion after bevacizumab 
treatment. But western blotting data of U87ΔEGFR cells and U251 cells indicated that the 
expression level of FGF13B were not changed after bevacizumab treatment. Microarray data 
for human specimens also showed same result, although we did not show FGF13A and 
FGF13B separately in this data. It is possible that FGF13B, which is mainly expressed in 
cytoplasm, is only increased in human specimens. These results may suggest that FGF13 is 
an innate factor which drives glioma invasion, and glioma cells remain dependent on FGF13 
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for their invasion after bevacizumab treatment. Delay et al. reported that patients in their 
secondary dataset with high expression of FGF13 before bevacizumab treatment showed 
shorter overall survival after bevacizumab treatment (19). Combination of some drugs like 
cilengitide (6) or altiratinib (38) with bevacizumab were previously reported to suppress 
bevacizumab-induced glioma invasion, therefore, FGF13 also could be a novel target of 
bevacizumab treatment.  
In conclusion, our research first reported that FGF13 was mainly expressed in the 
cytoplasm of glioma cells and in the invasive edges of tumor specimens, and was therefore 
related to glioma invasion. Furthermore, FGF13 was also related to bevacizumab-induced 
glioma invasion. Our results suggested that FGF13 could be a promising new target to treat 
and prevent glioma invasion.  
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Materials and Methods 
 
Culture of established cell lines and glioma stem cells 
As previously reported, the canine glioma cell lines, J3T-1 and J3T-2, were derived from the 
same parental glioma cells (J3T) and were characterized (8, 39). The J3T cell line was a gift 
from Dr. Michael E. Berens at Barrow Neurological Institute (40). The A172, and Gli36Δ5 
(41) cells were obtained from Dr. E. A. Chiocca at Massachusetts General Hospital, Boston, 
MA, USA. The U87ΔEGFR and U251 cells were obtained from Dr. Balveen Kaur at Ohio 
State University, Columbus, OH, USA. The human glioblastoma derived cancer stem cell 
line, MGG8 and MGG23 cells were provided by Dr. Hiroaki Wakimoto at Massachusetts 
General Hospital. NHA cells were purchased from Takara Bio Inc. (Shiga, Japan). The J3T-
1, J3T-2, U87ΔEGFR, U251, LNZ308, A172, and Gli36Δ5 were cultured in Dulbecco’s 
Modified Eagle’s Medium (DMEM) containing 10% fetal bovine serum (FBS), 100 U of 
penicillin, and 0.1 mg mL-1 of streptomycin. The human glioblastoma derived cancer stem 
cell line, MGG8 and MGG23 cells were cultured as previously described (42) (18). For 
hypoxic conditions, the cells were cultured with 1% O2 or in medium containing 100 μM 
deferoxamine mesylate (Sigma-Aldrich, St. Louis, MO, USA). U87ΔEGFR, U251 and 
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A172 were authenticated by Promega (Madison, WI, USA ) via short tandem repeat (STR) 
profiling in December 2016. Mycoplasma is negative in all cells. 
 
Human glioblastoma specimens 
Twenty-five human glioblastoma specimens were randomly selected from 80 glioblastoma 
patients treated at the Okayama University Hospital between 2006 and 2016. The study 
(1603-070) was approved by the ethical committee of the Okayama University Graduate 
School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. Informed 
consent was obtained from all patients included in the study. For pathological analyses, we 
defined the tumor core and the invasion edge as corresponding to the cellular tumor and 
infiltrating tumor as defined in the IVY Glioblastoma Atlas Project 
(http://glioblastoma.alleninstitute.org/). Among 25 specimens, all included the region of 
tumor core, but only 8 specimens had the region of invasion edge. We also evaluated FGF13 
mRNA of 12 corresponding tumors from frozen samples that were available for qRT-PCR. 
 
Microarray assays 
Total RNA from J3T-1 and J3T-2 cells were isolated using the RNeasy kit (Qiagen, Santa 
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Clarita, CA, USA) and were analyzed using a GeneChip® Canine Genome 2.0 Array 
(Affymetrix, Santa Clara, CA, USA). The microarray analyses were performed by Takara 
Bio. Inc.. Briefly, biotinylated cRNA was synthesized by the GeneChip® 3'IVT Express Kit 
(Affymetrix) from 250 ng total RNA, according to the manufacturer's instructions. 
Biotinylated cRNA yields were checked with the NanoDrop ND-2000 Spectrophotometer 
(ThermoFisher Scientific, Scotts Valley, CA, USA). Following fragmentation, 10 µg of 
cRNA were hybridized for 16 hours at 45˚C on the GeneChip® Canine Genome 2.0 array. 
Arrays were washed and stained using the GeneChip® Fluidics Station 450 instrument 
(Affymetrix). Arrays were scanned using the GeneChip® Scanner 3000 7G (Affymetrix). 
Single array analyses were calculated using the Microarray Suite version 5.0 (MAS5.0) with 
Affymetrix default settings and global scaling as the normalization methods. The trimmed 
mean target intensity of each array was arbitrarily set to 500. Genes with absolute value of 
the fold change (FC) at least 2.0 and p-value < 0.05 were considered to be significantly 
regulated. GO enrichment analysis was performed using the functional annotation tool 
Database for Annotatio Visualization and Integrated Discovery (DAVID) 6.8 and significant 
GO terms were identified at p < 0.05 (43). All data are deposited in the Gene Expression 
Omnibus (accession number GSE88740).  
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RNA isolation, cDNA synthesis, and quantitative reverse transcription-polymerase chain 
reaction (qRT-PCR) 
We isolated total RNA  from the cell lines or human glioblastoma specimens, and 
synthesized cDNA with the SuperScript™ III First-Strand Synthesis System (Invitrogen, 
Carlsbad, CA, USA). The qRT-PCR reactions were then performed and detected using the 
StepOnePlusTM system (Life Technologies, Carlsbad, CA, USA).  
As an internal control, we used β-actin (ACTB) mRNA. Primers were designed with the 
Primer3 Plus software and were purchased from Invitrogen. The primer sequences used were 
as follows: 
Canine FGF13 primers: forward, 5′-GTAGCCAGTGAGGGCAAGAC-3′; reverse, 5′- 
AGTCTGCTGCACAAGCTCAA-3′. 
Canine ACTB primers: forward, 5′-TGCGTGACATCAAGGAGAAG-3′; reverse, 5′- 
AGGAAGGAAGGCTGGAAGAG-3′. 
Human FGF13 primers: forward, 5′-ACAAGCCTGCAGCTCATTTT-3′; reverse, 5′- 
CATTGTGGCTCATGGATTTG-3′. 
Human CA9 primers: forward, 5’-TATCTGCACTCCTGCCCTCT-3’, 5’- 
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ACAGGACAGTTACCGGCTC-3’. 
Human ACTB primers: forward, 5′-GGACTTCGAGCAAGAGATGG-3′; reverse, 5′- 
AGCACTGTGTTGGCGTACAG-3′. 
 
Plasmids, RNA interference, and lentiviruses 
The human FGF13B plasmids were purchased from GeneCopoeia (Rockville, MD, USA). 
We added a nuclear export signal to the N-terminus of FGF13B to avoid the nuclear import 
of overexpressed FGF13B, as previously reported (14). Small interfering RNA (siRNA) 
against canine or human FGF13 and negative control RNA were obtained from Thermo 
Fisher Scientific and transfected with Lipofectamine® 3000. The lentivirus encoding 
scramble short hairpin RNA (shRNA) and shRNA against canine or human FGF13 were 
prepared using the pLKO.1, psPAX2, and pMD2.G plasmids (Addgene, Cambridge, CA, 
USA), 293FT cells, and FuGENE® 6 Transfection Reagent (Promega) according to 
manufacturer’s recommendations.  
 
Migration and invasion assay 
For scratch assays, we seeded each cells at 70–90% confluency. One day before the scratch, 
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we changed the medium into DMEM with 0.1% FBS for starvation. Then, the cells were 
scratched, cultured for 24 hours, and observed. The transwell and invasion assay were 
performed using a ThinCertTM Tissue Culture Insert (Greiner Bio-One, Frickenhausen, 
Germany) and a BioCoat Matrigel invasion chamber (BD Bioscience, Franklin Lakes, NJ, 
USA) according to the manufacture’s instructions, respectively. In brief, we seeded 1×105 
cells in DMEM with 0.1% FBS in the upper chamber and filled with DMEM with 10% FBS 
in lower chamber. After 24 hours incubation, the filters of inserts were fixed with methanol 
and stained with Giemsa solution. We calculated the number of invading cells on the lower 
surface of the filter. 
 
Western blot analysis 
We prepared cell lysates and proteins using RIPA buffer and PMSF (Cell Signaling 
Technology), and isolated tubulin as previously described (14). And then, we performed 
western blotting as previously described (44).  
After blocking, the membranes were incubated overnight with primary antibodies [anti-
FGF13, Sigma-Aldrich, 1:300 dilution; anti-β-actin, Sigma-Aldrich, 1:5000 dilution; anti-
acetylated-tubulin, Abcam, Cambridge, UK, 1:1000; anti-α-tubulin, Cell Signaling 
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Technology, Danvers, MA, USA, 1:1000] at 4°C. The secondary antibodies used were HRP-
conjugated anti-mouse IgG and HRP-conjugated anti-rabbit IgG (Cell Signaling Technology, 
1:5000). HRP signals were analyzed by the VersaDoc® molecular imaging system (Bio-Rad, 
Hercules, CA, USA). 
 
Immunofluorescence and immunohistochemistry 
Immunofluorescent and immunohistochemistry analyses were carried out as previously 
described (6) (11). Following antibodies were used for immunofluorescent: anti-FGF13, 
1:100; anti-β-tubulin, Sigma-Aldrich, 1:1000; anti-vimentin, DakoCytomation, Carpentaria, 
CA, USA, 1:100; anti-ki67, Leica Biosystems, Wetzlar, Germany, 1:150; Alexa Fluor® 488- 
or Alexa Fluor® 594-conjugated antibodies, Life Technologies, 1:250. F-actin was stained 
using the CytoPainter F-actin Labeling Kit (Abcam) according to the manufacturer’s protocol. 
Immunofluorescent images were obtained with a confocal laser microscope (LSM 780; Zeiss, 
Jena, Germany).  
The following antibodies were used for immunohistochemistry: anti-FGF13, 1:100; anti-
HLA, Abcam, 1:100; anti-CD31, Abcam, 1:50; anti-Iba-1, Abcam, 1:250; anti-goat IgG-
HRP; Santa Cruz, 1:200. The Dako Envision®+ System-HRP Kit was then used in accordance 
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with the manufacturer’s protocol (DakoCytomation) and the sections were counterstained 
with hematoxylin. Immunohistochemistry samples were observed with the BZ-8100 
microscope (Keyence, Osaka, Japan). 
 
Apoptosis assay 
Apoptotic tumor cells were detected using an In Situ Cell Death Detection Kit (Roche, 
Mannheim, Germany) according to manufacture’s protocol.  
 
Water soluble tetrazolium-1 (WST-1) assay 
For analyses of glioma cell proliferation, the WST-1 assay was performed according to the 
manufacturer’s protocol (Roche). 
 
In vivo experiments 
All experimental animals were housed and handled in accordance with the guidelines of the 
Okayama University Animal Research Committee and all of the procedures and animal 
protocols were approved by the Committee on the Ethics of Animal Experimentation at 
Okayama University. Six week-old female athymic or SCID mice were purchased from Clea 
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Japan Inc. (Tokyo, Japan) or Charles River Laboratories Japan (Yokohama, Japan), 
respectively. The J3T-2, MGG8, MGG23, or U87ΔEGFR cells (2 × 105 cells) expressing 
scramble short hairpin RNA (shRNA) or shRNA against canine or human FGF13 were 
stereotaxically injected into the right frontal lobe (3 mm lateral to the midline, 1 mm anterior 
to the coronal suture, 3 mm depth from the dura), using a stereotactic frame (Narishige, Tokyo, 
Japan) and Hamilton syringe (Hamilton, Reno, NV, USA) as previously described (6). Mice 
bearing U87ΔEGFR cells were randomized into control or treatment groups. We 
administered PBS or bevacizumab (6 mg/kg) intraperitoneally three times per week, which 
we started on day 5 after implantation. Bevacizumab was provided by Chugai Pharmaceutical 
Co. (Tokyo, Japan). Group allocation was not blinded.  
 
Statistical analyses 
Statistical analyses were performed using SPSS statistical software (version 20; SPSS, 
Chicago, IL, USA). The results of percentages of FGF13 positive cells, the MIB-1 labeling 
indices, vessel density, percentages of TUNEL positive-cells and the relative mRNA and 
protein expression were analyzed using Student’s t-tests. The results of relative mRNA 
expression, migration assays, WST-1 assays, percentages of TUNEL-positive cells and 
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invasion assays were analyzed using the two-way analysis of variance (ANOVA) test. 
Kaplan-Meier curves were compared using the log-rank test. P values of < 0.05 were 
considered statistically significant. For statistical analyses, experimental replicates from at 
least three samples were compiled for each experiment, unless otherwise stated in the figure 
legend. The data represent the mean ± SEM.  
Supplementary Information accompanies the paper on the Oncogene website 
(http://www.nature.com/onc). 
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Figure legends 
 
Fig. 1 
Distribution pattern of fibroblast growth factor 13 (FGF13) in glioma cell lines and human 
glioma specimens. 
(A) Immunofluorescent staining of J3T-2 cells showed FGF13 was more dominant in the 
cytoplasm than nucleus. DAPI = 4, 6-diamidino-2-phenylindole, used for nuclear staining. 
(B) Immunohistochemical staining of FGF13 in normal human brains showed FGF13 was 
mainly expressed in the nucleus of the neuron.  
(C, D) The expression pattern of FGF13 in the tumor core and the invasion edge of 25 
glioblastoma patients were evaluated using immunohistochemistry (IHC). Quantification 
was performed in randomly-selected three fields in each region. The representative results 
from cases 18 and 20 are shown in (C). The expression level of FGF13 mRNA determined 
from quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was compared 
to the immunohistochemical staining of FGF13 from 12 corresponding tumors. The median 
expression values for FGF13 mRNA with upper and lower quartiles (25–75%) are shown and 
the expression levels of FGF13 mRNA and proteins were significantly correlated. The 
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correlations were determined using the Student’s independent t-test.  
(E) Western blotting confirmed FGF13B was more predominant than FGF13A. 
Representative western blots from three experiments are shown. Numerical values on the 
right side of panel represent quantification of the relative protein level by densitometry. 
Molecular weight markers are shown in parentheses. 
(F) At the invasive edge, most tumor cells expressed FGF13 in the cytoplasm (n = 8). 
However, in the tumor core, the number of FGF13 positive cells varied in each patient (n = 
25). The statistical significance was calculated by the Student’s t-test.*p < 0.01. 
(G) Data of IVY Glioblastoma Atlas Project also showed that FGF13 was more expressed in 
the area of both leading edge and infiltrating tumor than cellular tumor, perinecrotic zone, 
hyperplastic blood vessels and microvascular proliferations. 
(H) Data from the Cancer Genome Atlas (TCGA) project showed that FGF13 was more 
expressed in proneural and neural subtypes than in classical and mesenchymal subtypes. 
Scale bars, 50 μm (A–C). 
 
Fig. 2 
FGF13 was involved in glioma migration in vitro. 
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(A) Relative expression levels of FGF13 mRNA were decreased by siRNA in J3T-2, 
U87ΔEGFR, U251, and LNZ308 cells (n = 3). 
(B) Knockdown of FGF13 by siRNA decreased both FGF13A and FGF13B protein levels in 
U87ΔEGFR, U251, and LNZ308 cells.  
(C, D) Knockdown of FGF13 by siRNA decreased the migratory activity of J3T-2 (n = 10), 
U87ΔEGFR (n = 10), U251 (n = 10), and LNZ308 cells (n=5). 
(E) Knockdown of FGF13 by siRNA did not affect the cell viability of J3T-2, U87ΔEGFR, 
U251, and LNZ308 cells (n = 5). Each cell sample was transfected with siRNA, and 48 hours 
later cell viability was calculated using the WST-1 assay.  
Data are shown (A, D and E) as the mean ± SEM. Statistical significance was calculated by 
ANOVA with Dunnett’s post hoc test. *p < 0.05 
NC = negative control siRNA. 
 
Fig. 3 
FGF13 was involved in glioma invasion in the J3T-2 xenograft model and reduction of 
FGF13 improved overall survival. 
(A) The relative expression levels of FGF13 mRNA were decreased by shRNA in J3T-2 cells 
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(n = 3).  
(B, C) Immunohistochemical staining [tumor cells: vimentin, red; nuclei: DAPI (4′, 6-
diamino-2-phenylindole), blue] showed that the tumor border of samples from the J3T-2 cells 
transfected with lentivirus encoding FGF13 shRNA (J3T-2 FGF13 shRNA) was clear. The 
cell density in the tumor border was significantly less in the J3T-2 FGF13 shRNA samples. 
Scale bars, 100 µm.  
(D, E) Knockdown of FGF13 by shRNA did not change the MIB-1 labeling index (n = 4).  
(F, G and H) Knockdown of FGF13 did not induce cell apoptosis and increase the number of 
vessels (n=4)  
(I) Kaplan-Meier survival curves of intracranial xenografts with J3T-2 expressing FGF13 
shRNA or scramble shRNA. The survival percentage with time of the J3T-2 expressing 
FGF13 shRNA samples was significantly longer than that of the J3T-2 scrambles with shRNA 
(median survival = 59.5 versus 49 days, respectively) (n = 8). Statistical significance was 
calculated by the log rank test.  
Data are shown (A, C, E, F, and H) as the mean ± SEM. Statistical significance was calculated 
by the Student’s t-test. *p < 0.05. 
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Fig. 4 
FGF13 was involved in glioma invasion in the human glioblastoma-derived cancer stem cell 
xenograft model and reduction of FGF13 improved overall survival. 
(A) The relative expression level of FGF13 mRNA was decreased by shRNA in MGG8 cells 
(n = 3).  
(B, C) Immunohistochemical staining of representative sections of the intracranial xenograft 
with MGG8 cells expressing FGF13 shRNA or scramble shRNA. Tumor cells were stained 
with anti-human HLA antibody and the number of tumor cells in the ipsilateral and 
contralateral cortex was assessed (n = 4). Invasiveness was impaired in MGG8 cells 
transfected with lentivirus encoding FGF13 shRNA. Scale bars, 50 µm. 
(D) Knockdown of FGF13 did not induce cell apoptosis (n=4).  
(E) Kaplan-Meier survival curves of intracranial xenografts with MGG8 cells expressing 
FGF13 shRNA#1, FGF13 shRNA#2, or scramble shRNA. The survival time of MGG8 
samples expressing either FGF13 shRNA#1 or FGF13 shRNA#2 (median survival = 61 or 
61.5 days, respectively) were significantly longer than that of the MGG8 scramble shRNA 
expressing samples (median survival = 55.5 days) (n = 8). Statistical significance was 
calculated by the log rank test. **p < 0.02. 
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Data are shown (A, C and D) as the mean ± SEM. Statistical significance was calculated by 
ANOVA with the Dunnett’s post hoc test. *p < 0.01. 
 
Fig. 5 
FGF13 colocalized with tubulin in the cytoplasm, stabilized tubulin and the FGF13 
expression in glioma was negatively regulated by hypoxic condition. 
(A) Immunohistochemical staining (FGF13, green; β-tubulin, red; F-actin, blue) of J3T-2 
cells showed that cytoplasmic FGF13 was colocalized with tubulin. 
(B) FGF13 stabilized and protected microtubules from nocodazole-induced tubulin 
depolymerization. Total, soluble and insoluble tubulins were prepared from normal A172 
cells or A172 cells overexpressing FGF13B after treatment with DMSO or nocodazole (5µM, 
in DMSO) for 15 minutes at 37℃. DMSO = dimethyl sulfoxide; Ace-tubulin = acetylated 
tubulin; Tyr-tubulin = tyrosinated tubulin. Numerical values under the panel represent 
quantification of the relative protein level (Ace-tubulin / Tyr-tubulin) as assessed by 
densitometry. 
(C) The expression levels of FGF13 in both U87ΔEGFR and U251 cell lines were decrease 
by hypoxia or deferoxamine mesylate (DFOM, 100 μM). 
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Fig. 6 
Knockdown of FGF13 inhibited bevacizumab-induced glioma invasion. 
(A) The expression level of FGF13 in the U87Δ EGFR was almost the same after 
bevacizumab treatment. 
(B, C) The expression level of FGF13 mRNA in five glioblastoma patients at either pre- or 
post-bevacizumab treatment. There was no significant difference on FGF13 mRNA 
expression level between pre- and post-bevacizumab treatment. Bev = bevacizumab. 
(D) The relative expression level of FGF13 mRNA was decreased by shRNA in U87ΔEGFR 
cells (n = 3). *p < 0.01. 
(E, F) Immunohistochemical staining of untreated U87ΔEGFR orthotopic tumors showed the 
expansion of the tumor with well-defined borders (E, left upper panel). After treatment with 
bevacizumab, the tumor border became irregular with tumor invasion (E, right upper panel). 
The invasiveness after bevacizumab treatment was assessed using the distance between the 
tumor mass edge and invasive lesion (F). The invasiveness was remarkably decreased in the 
U87ΔEGFR cells transfected with lentivirus encoding FGF13 shRNA (n = 4) compared with 
that of the U87ΔEGFR cells transfected with lentivirus encoding scramble shRNA (n = 5).  
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Data are shown as the mean ± SEM. Statistical significance was calculated by the Student’s 
t-test. *p < 0.01. **p < 0.05. Scale bars, 200 μm (E). 
 
Table 1. GO analysis of significantly up-regulated genes in J3T-1 
 
GO term Process description P value Fold enrichment 
0005925 Focal adhesion 3.4E-9 4.2 
0070062 Extracellular exosome 2.6E-5 1.6 
0005887 Integral component of plasma membrane 3.8E-3 1.8 
0005615 Extracellular space 4.3E-3 1.7 
0009897 External side of plasma membrane 2.0E-2 2.7 
0005623 Cytosol 4.4E-2 1.5 
0030173 Integral component of Golgi membrane 4.6E-2 4.9 
 
  
Table 2. GO analysis of significantly up-regulated genes in J3T-2 
 
GO term Process description P value Fold enrichment 
0070062 Extracellular exosome 1.0E-7 1.8 
0005911 Cell-cell junction 2.5E-3 3.8 
0000790 Nuclear chromatin 5.8E-3 3.0 
0030027 Lamellipodium 8.0E-3 3.5 
0005615 Extracellular space 9.0E-3 1.6 
0005768 Endosome 1.1E-2 3.0 
0005874 microtubule 1.1E-2 3.3 
0001725 Stress fiber 1.5E-2 5.2 
0043234 Protein complex 2.3E-2 2.6 
0005737 Cytoplasm 2.5E-2 1.3 
0005856 Cytoskeleton 2.7E-2 3.0 
0030864 Cortical actin cytoskeleton 3.2E-2 5.7 
0030424 Axon 3.2E-2 2.9 
0005578 Proteinaceous extracellular matrix 3.6E-2 2.4 
0005925 Focal adhesion 4.3E-2 1.9 
0005654 Nucleoplasm 4.4E-2 1.4 
0005584 Collagen type I trimer 4.6E-2 42.7 
 
  
Supplementary Table 1. Silencing of FGF13 did not alter perimeter of tumor cells 
 
Name of cell lines siRNA N.C. siRNA #1 siRNA #2 Statistical significance 
(Compared with N.C.) 
J3T2 191.5 1±14.8 177.0±11.5 177.9±13.4 N.S. 
U87ΔEGFR 103.4±11.8 85.0±11.3 98.7±9.4 N.S. 
U251 197.6±16.7 171.0±15.7 160.8±9.6 N.S. 
LNZ308 137.2±6.3 129.0±6.5 128.1±7.1 N.S. 
A172 212.5±14.5 202.9±24.9 199.0±15.6 N.S. 
Gli36Δ5 136.1±10.2 162.0±13.8 157.2±14.3 N.S. 
 
Data are shown as the mean ± SEM (µm). Statistical significance was calculated by ANOVA with Dunnett’s post hoc test. 
N.C. = negative control; N.S. = Not Significance 
  
Supplementary Table 2. Silencing of FGF13 did not alter area of tumor cells 
 
Name of cell lines siRNA N.C. siRNA #1 siRNA #2 Statistical significance 
(Compared with N.C.) 
J3T2 388.4±16.2 402.0±42.2 413.4±14.3 N.S. 
U87ΔEGFR 187.2±17.1 218.6±24.5 220.3±21.1 N.S. 
U251 772.0±80.7 918.1±83,2 847.0±86.9 N.S. 
LNZ308 972.1±75.1 848.1±96.8 869.6±69.9 N.S. 
A172 479.3±41.0 549.6±42.4 523.7±49.4 N.S. 
Gli36Δ5 866.2±75.2 720.0±69.3 888.2±90.7 N.S. 
 
Data are shown as the mean ± SEM (µm2). Statistical significance was calculated by ANOVA with Dunnett’s post hoc test. 
N.C. = negative control; N.S. = Not Significance 
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Supplementary Fig. 1 
Microarray analysis of J3T-2 compared with J3T-1 identified novel 
invasion-related gene, FGF13.
(A) Microarray analysis showed 791 differentially expressed genes 
that presenting fold changes > 2.0 between J3T-1 and J3T-2, which 
consisted of 418 genes overexpressed in J3T-1 and 373 genes 
overexpressed in J3T-2.
(B) FGF13 mRNA expression was markedly up-regulated in J3T-2 
than J3T-1 (n=6). Statistical significance was calculated by the 
Student’s T-test. *p < 0.01.
Supplementary Fig. 2
Microenvironmental cells like endothelial cells or macrophages did 
not express FGF13.
Serial section analysis in immunohistochemistry revealed that 
tumor cells expressed FGF13 (arrow head), however, endothelial 
cells (arrow, Fig. A) or macrophages (arrow, Fig. B) did not express 
FGF13.
Scale bar, 50 μm
A
B
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Supplementary Fig. 3
FGF13 expression in glioma subtypes.
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Supplementary Fig. 4 
FGF13 was involved in glioma invasion in vitro.
(A, B) Knockdown of FGF13 by siRNA decreased the invasion 
activity of J3T-2 and U87ΔEGFR cells (n=10). In contrast, silencing 
of FGF13 did not affect the invasion activity of A172 (n=10).
(C) A172 and Gli36Δ5 cell lines expressed very low levels of FGF13 
(n=6) compared with that of normal human astrocyte (NHA). 
(D) Silencing of FGF13 did not affect the migration activity of 
A172 and Gli36Δ5 cells. 
Data are shown as the mean ± SEM. Statistical significance was 
calculated by ANOVA with the Dunnett’s post hoc test. *p < 0.05. 
NC = negative control siRNA.
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Supplementary Fig. 5
Silencing of FGF13 did not induce apoptosis of glioma cell lines in 
vitro.
(A) Representative pictures from five experiments are shown. 
TUNEL-positive cells, green; DAPI = 4, 6-diamidino-2-phenylindole, 
blue. Bar = 50 μm. 
(B) Silencing of FGF13 did not induce apoptosis of glioma cell lines 
in vitro. (n=5)
Statistical significance was calculated by ANOVA with Dunnett’s
post hoc test.
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Supplementary Fig. 6
FGF13 was involved in glioma invasion in MGG23 and reduction 
of FGF13 improved overall survival.
(A) The relative expression level of FGF13 mRNA was decreased 
by shRNA in MGG23 cells (n = 3). 
(B, C) Knockdown of FGF13 in MGG23 impaired glioma invasion as 
well as MGG8 (n=3). Scale bars, 50 µm.
(D, E) Silencing of FGF13 had no effect on cell proliferation and 
angiogenesis (n=3).
(D) Kaplan-Meier survival curves of intracranial xenografts with 
MGG23 cells expressing FGF13 shRNA#1, FGF13 shRNA#2, or 
scramble shRNA. The survival time of MGG23 expressing either 
FGF13 shRNA#1 or FGF13 shRNA#2 (median survival = 68 or 65.5 
days, respectively) were significantly longer than that of scramble 
shRNA (58days) (n=8).
*p < 0.01, **p < 0.05
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Supplementary Fig. 7
The FGF13 expression was negatively regulated by hypoxia. 
(A, C) The relative expression of CA9 mRNA, which is a marker of 
hypoxic condition, was significantly up-regulated by 1% O2
(hypoxia) or deferoxamine mesylate (DFMO) in both U87ΔEGFR 
(A) and U251 (C) (n=3). 
(B, D) The relative expression of FGF13B protein was significantly 
decreased by 1% o2 (hypoxia) or deferoxamine mesylate (DFMO) 
in both U87ΔEGFR (B) and U251 (D) (n=4).
Data are shown as the mean ± SEM. Statistical significance was 
calculated by the Student’s T-test. *p < 0.05.
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Supplementary Fig. 8
Silencing of FGF13 decreased bevacizumab-induced invasion.
(A, B) Western blotting of U87ΔEGFR (A) and U251 (B) showed that the 
expression level of FGF13B did not alter after bevacizumab treatment 
(n=4). Statistical significance was calculated by the Student’s T-test.
(C, D) Double chamber assays showed that bevacizumab induced 
glioma invasion, but silencing of FGF13 inhibited the invasion of 
U87ΔEGFR (C) and U251 (D) (n=3). Statistical significance was 
calculated by Tukey’s post hoc test. NC = negative control siRNA.
(E) Immunohistochemical staining of a human glioma specimen (case 
25) showed FGF13 was expressed after bevacizumab treatment.
(F, G) Immunohistochemical staining of U87ΔEGFR cells transfected 
with scramble shRNA treated with bevacizumab showed bevacizumab-
induced invasion (F). In contrast, silencing of FGF13 decreased the 
invasiveness (G). The representative results are shown.
Data are shown as the mean ± SEM.  *p < 0.05.
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Supplementary Fig. 9 
Full scans of the immunoblots shown in the figure. Boxes indicated 
parts used in the figure and numbers indicated molecular weights.
